Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Items where Author is "Majidpoor, J."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Jump to: Article
Number of items: 37.

Article

(2023) Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses. Heliyon.

(2023) Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses. Heliyon.

(2023) Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

(2023) Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated. International immunopharmacology.

(2023) Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

(2023) Transforming growth factor-beta signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated. Journal of cellular and molecular medicine.

(2023) Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated. Journal of cellular and molecular medicine.

(2023) The impact of hypoxia on extracellular vesicle secretome profile of cancer. Medical oncology (Northwood, London, England).

(2023) The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

(2023) The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

(2022) CD8(+) T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives. Frontiers in immunology.

(2022) CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Frontiers in immunology.

(2022) Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

(2022) Checkpoint inhibitor/interleukin-based combination therapy of cancer. Cancer medicine.

(2022) Dysregulated metabolism: A friend-to-foe skewer of macrophages. International reviews of immunology.

(2022) Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated. Medical Oncology.

(2022) Extracellular vesicle isolation, purification and evaluation in cancer diagnosis. Expert reviews in molecular medicine.

(2022) Extracellular vesicle-based checkpoint regulation and immune state in cancer. Medical oncology (Northwood, London, England).

(2022) Glial Response to Intranasal Mesenchymal Stem Cells in Intermittent Cuprizone Model of Demyelination. Neurotoxicity research.

(2022) Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

(2022) Key promoters of tumor hallmarks. International journal of clinical oncology.

(2022) NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives. Medical oncology (Northwood, London, England).

(2022) Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy. Cellular Oncology.

(2022) VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated. Life sciences.

(2022) The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life sciences.

(2021) Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cellular Oncology.

(2021) (Im)maturity in Tumor Ecosystem. Frontiers in oncology.

(2021) Interleukin-2 therapy of cancer-clinical perspectives. International Immunopharmacology.

(2021) Steps in metastasis: an updated review. Medical Oncology.

(2021) The current knowledge concerning solid cancer and therapy. Journal of biochemical and molecular toxicology.

(2021) The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clinical immunology (Orlando, Fla.).

(2020) Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance. Journal of Cancer Research and Clinical Oncology.

(2020) The effect of the “segment” of spinal cord injury on the activity of the nucleotide-binding domain-like receptor protein 3 inflammasome and response to hormonal therapy. Cell Biochemistry and Function.

(2019) Macrophage polarity in cancer: A review. Journal of Cellular Biochemistry.

(2018) Post-treatment of melatonin with CCl4 better reduces fibrogenic and oxidative changes in liver than melatonin co-treatment. Journal of Cellular Biochemistry.

(2018) Post-treatment of melatonin with CCl4 better reduces fibrogenic and oxidative changes in liver than melatonin co-treatment. Journal of Cellular Biochemistry.

(2017) Preconditioning with melatonin improves therapeutic outcomes of bone marrow-derived mesenchymal stem cells in targeting liver fibrosis induced by CCl4. Cell and Tissue Research.

This list was generated on Fri Mar 29 05:22:42 2024 +0430.